<code id='600B20F4C1'></code><style id='600B20F4C1'></style>
    • <acronym id='600B20F4C1'></acronym>
      <center id='600B20F4C1'><center id='600B20F4C1'><tfoot id='600B20F4C1'></tfoot></center><abbr id='600B20F4C1'><dir id='600B20F4C1'><tfoot id='600B20F4C1'></tfoot><noframes id='600B20F4C1'>

    • <optgroup id='600B20F4C1'><strike id='600B20F4C1'><sup id='600B20F4C1'></sup></strike><code id='600B20F4C1'></code></optgroup>
        1. <b id='600B20F4C1'><label id='600B20F4C1'><select id='600B20F4C1'><dt id='600B20F4C1'><span id='600B20F4C1'></span></dt></select></label></b><u id='600B20F4C1'></u>
          <i id='600B20F4C1'><strike id='600B20F4C1'><tt id='600B20F4C1'><pre id='600B20F4C1'></pre></tt></strike></i>

          explore

          explore

          author:hotspot    Page View:29286
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          Study: Why relieving medical debt did not improve financial outcomes
          Study: Why relieving medical debt did not improve financial outcomes

          AdobePhilanthropistsandfoundationsliketheoneIworkfortakealotofcalculatedrisks.Weinvestinresearch,adv

          read more
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more

          Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

          CTscansshowedthatthepatientinitiallyrespondedtolorlatinib(left).Buteightmonthslater,themetastaticliv